Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Homeocare Laboratories, Inc.
WARNING LETTER
•Homeocare Laboratories, Inc.•December 13, 2019

Homeocare Laboratories, Inc. – FDA Warning Letter, Dec 13, 2019

Record Details

The FDA issued a Warning Letter to Homeocare Laboratories, Inc. following an inspection from December 2-13, 2019, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated. The firm manufactures "BIOIDENTICAL USP PROGESTERONE CREAM," an unapproved new drug. Additionally, FDA review of their website in March and May 2020 revealed other unapproved new drugs, including "Acute Asthma Relief," "Anxiety Relief," "Cholestop," "Fibromyalgia Relief," "HBP Relief," "IBS Relief," "Insomnia Relief," "Memo-Rx," "Stress Relief," and "Vigofem Plus For Women." These products are concerning due to claims for serious conditions and potential for patients to forgo effective treatments.

Key CGMP violations include: 1. **Lack of finished product testing (21 CFR 211.165(a)):** The firm released drugs without testing for identity, strength, content uniformity, or impurities. 2. **Inadequate component testing and supplier qualification (21 CFR 211.84(d)(1) & (2)):** The firm used components from unqualified suppliers without adequate testing or validating supplier COAs. 3. **Failure to validate cleaning procedures (21 CFR 211.67(a)):** Shared equipment was used for potent drugs like progesterone without validated cleaning

Company
Homeocare Laboratories, Inc.
Inspection date
December 13, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Diana Amador-Toro (District Director)
View Company Profile

ID · 74b15a31-82ec-4307-a28b-94585430cd24

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 CFR 211.165(a)21 CFR 211.84(d)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Homeocare Laboratories, Inc.
  • 483 - 2024-03-20March 20, 2024
  • 483 - 2023-02-21February 21, 2023
  • 483 - 2021-06-04June 4, 2021
  • 483 - 2019-12-13December 13, 2019
  • WARNING_LETTER - 2017-01-11January 11, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Homeocare Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.